German maker of branded generic drugs, specialty pharmaceuticals and OTC health products, also producing allergy immunotherapies.
German maker of branded generic drugs, specialty pharmaceuticals and OTC health products, also producing allergy immunotherapies.
Grows largely by buying established brand-name drugs and making them in its own German plants, so it earns manufacturing margin on mature products rather than depending on new launches. The founding Beier family remains the controlling shareholder. It also filled COVID vaccine doses under contract for BioNTech.
In one line: A German branded-generics maker like a smaller Perrigo/Amneal.
Moat: narrow (brand, regulatory licence, scale). Established branded-generic portfolio and German manufacturing base, but generics pricing is competitive.
Headquarters: Grafelfing, Germany · Founded: 1991 · Employees: 3,500
Size Dermapharm (DMP.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $1.85B, the 108th largest of 198 Germany companies the cockpit tracks. Shares closed at €34.05 on 18 Nov 2026.
Performance Over six months the shares fell 29.1%, against -4.7% for the median peer and -0.9% for the Germany market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 1.7% over the last twelve months (peer median +10.0%); the operating margin is 20.9% (peer median 12.7%).
Valuation It trades at 13.2× forward earnings against a peer median of 18.9× (8th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.1 points above its cost of capital (6.1% WACC).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.18B | €1.16B | €1.18B | €1.14B | €1.02B |
| Revenue growth | — | -1% | +4% | +11% | — |
| Gross profit | €399M | €392M | €390M | €343M | €370M |
| EBITDA | €353M | €314M | €298M | €305M | €362M |
| Net income | €130M | €132M | €114M | €62.4M | €134M |
| Free cash flow | €151M | €139M | €114M | €150M | €247M |
| Capital expenditure | €51.6M | €42.1M | €38.2M | €41.5M | €39.0M |
| Total debt | €1.12B | €1.05B | €980M | €1.08B | €516M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dermapharm DMP.DE | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Perrigo PRGO | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Hikma Pharmaceuticals HIK.L | $4.58B | +15% | +2% | 20% | 9.8× | 2.0% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| ALK-abello A/S ALK-B.CO | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DMP.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.0% | +0.7% | 4th lowest of 21 |
| 6-month return | -29.1% | -4.7% | 2nd lowest of 21 |
| Distance from 52-week high | -34.4% | -28.3% | 8th lowest of 21 |
| Revenue growth (TTM) | +1.7% | +10.0% | 6th lowest of 21 |
| Operating margin | 20.9% | 12.7% | 7th highest of 21 |
| Forward P/E | 13.2× | 18.9× | 8th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -3.4% | 1.2% | 4th least demanding of 14 |
| Growth delivered (Del g) | +8.0% | +7.8% | 7th highest of 14 |
| Hurdle (Req g minus delivered) | -11.4 pp | -12.8 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +5.1 pp | +0.7 pp | 9th highest of 21 |
| EV / EBITDA | 7.6× | 18.2× | 2nd cheapest of 10 |
| Net debt / EBITDA | 2.8× | 0.7× | 2nd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |